anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,055,385. Sugar agglomerates. AMERICAN SUGAR CO. April 2, 1964 [April 3, 1963], No. 13749/64. Headings A2B and A2E. A method of producing a sugar product comprises concentrating at a temperature not above 130C., a sucrose-containing syrup to 95-97% by weight solids, said syrup not containing more than 15% by weight non sucrose solids based on the solids content of the syrup, subjecting the resultant concentrate to a cooling operation with vigorous agitation to produce aggregates comprising fondant size sucrose crystals, the cooling operation being carried out in the substantial absence of water in contact with the aggregates and subjecting the aggregates to drying and further cooling such that the product has a moisture content of not more than 1% by weight. The non sucrose solids may consist of inverted sucrose, corn syrups, potato syrups, dextrose, maltose, lactose or molasses. The sugar product may be mixed with additives e.g. phosphoric acid, sodium phosphate, sodium hydrogen phosphate, potassium, calcium and magnesium phosphate, citric acid, ascorbic acid, vitamins, garlic, chocolate, cinnamon, carboxymethylcellulose, microcrystalline cellulose, tapioca starch, corn starch, potato syrup, honey and maple syrup. As shown, a syrup blend is mixed in container 11 from which it is fed to concentrator 24 via control rotameter 19, control valve 20 and heater 21. From concentrator 24 the concentrated syrup is passed to vapour separator 26 maintained under reduced pressure by pump 29. Hot concentrated syrup is passed to beater crystallizer 39 in which the syrup is crystallized and the aggregates of the crystals are formed. Vapour hood collects and withdraws vapours from beater crystallizer 39. Water is circulated through a jacket surrounding the crystallizer 39. The aggregates are passed to air drier and air cooler 50. The dried aggregates are passed to screening unit 62 directly or via mill 60. Aggregates of too great a size are returned to mill 60 and fines may be returned to crystallizer 39 or mixed with additives.
A system for an ocular gene therapy is provided. The system includes one or more optimized transgenes. The one or more optimized transgenes include pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65. The optimized transgenes pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65 have shown to exhibit enhanced RPE65 gene expression when compared to wild type RPE65 gene transfer in suitable models. These optimized genes may enhance therapeutic response during LCA2 gene therapy. The present invention also provides a process for preparing the optimized transgene for an ocular gene therapy.
Rice bran, which is abundant in dietary fiber and phytochemicals, provides multiple health benefits. Nonetheless, its effects on neuroinflammation and gut microbiota in postmenopausal conditions are still not well understood. This study investigated the effects of rice bran and/or tea seed oil supplementation in d-galactose-injected ovariectomized (OVX) old mice fed a fructose drink. The combination of d-galactose injection, ovariectomy, and fructose drink administration creates a comprehensive model that simulates aging in females under multiple metabolic stressors, including oxidative stress, estrogen deficiency, and high-sugar diets, and allows the study of their combined impact on metabolic disorders and related diseases. Eight-week-old and 6-8-month-old female C57BL/6 mice were used. The mice were divided into six groups: a sham + young mice, a sham + old mice, an OVX + soybean oil, an OVX + soybean oil with rice bran, an OVX + tea seed oil (TO), and an OVX + TO with rice bran diet group. The OVX groups were subcutaneously injected with d-galactose (100 mg/kg/day) and received a 15% (v/v) fructose drink. The rice bran and tea seed oil supplementation formed 10% of the diet (w/w). The results showed that the rice bran with TO diet increased the number of short-chain fatty acid (SCFA)-producing Clostridia and reduced the number of endotoxin-producing Tannerellaceae, which mitigated imbalances in the gut-liver-brain axis. Rice bran supplementation reduced the relative weight of the liver, levels of hepatic triglycerides and total cholesterol; aspartate transaminase and alanine aminotransferase activity; brain levels of proinflammatory cytokines, including interleukin-1β and tumor necrosis factor-α; and plasma 8-hydroxy-2-deoxyguanosine. This study concludes that rice bran inhibits hepatic fat accumulation, which mitigates peripheral metaflammation and oxidative damage and reduces neuroinflammation in the brain.
<P>PROBLEM TO BE SOLVED: To allow a patient prescribed with medicine at a hospital or the like to easily check the content of the prescription by means of an information terminal such as a cellphone.  <P>SOLUTION: A user carries out a registration process for pre-registering user information including at least his or her mail address. When the registered user is to have medicine prepared by an affiliate pharmacy according to the prescription, the prescription information is input and sent to an IMS server. Thereafter, the prescription information is sent from the IMS server to the user's information terminal by email. To provide medicine duplication information, the duplication information is further pre-registered; when the prescription information is input, the database is searched for the user's previous prescription information to determine if there is duplication of medicine between the medicine information extracted and newly input prescription information; if there is duplication, this is reported to the user by the email.  <P>COPYRIGHT: (C)2004,JPO
The intervention only has one arm. All participants will be provided 4 sessions of guided self-help intervention to be completed once weekly.
Disclosed is a method of photodynamic therapy that includes introducing a selective photocytotoxic compound to a body having a target cell, wherein the selective photocytotoxic compound is configured to selectively attach to or enter the target cell. The method further includes activating the selective photocytotoxic compound with a light source. Further disclosed is a method that includes introducing a selective photoluminescent compound to a body having a target material. The selective photoluminescent compound is configured to selectively attach to or enter the target material. The method includes introducing an activating light to the selective photoluminescent compound, wherein the photoluminescent compound is configured to absorb the activating light and emit an emission light having a different wavelength than the activating light for diagnosis and locating diseased areas. The method further includes activating a photocytotoxic compound with the emission light of the selective photoluminescent compound. A novel light source is further disclosed.
In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450, CYP3A4, CYP1A2, and CYP2C. Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil. Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics. Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil. 

Ivabradine

Concurrent use of verapamil increases exposure to ivabradine and may exacerbate bradycardia and conductions disturbances. Avoid concomitant use of ivabradine and verapamil.
Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
The invention provides application of a triterpene compound and a Parkinson's disease treatment medicine. The application comprises blocking of mutual combination between autophagy skeleton protein Beclin1 and an autophagy inhibiting factor Bcl-2 so as to induce nerve cell autophagy, and preparation of a Parkinson's disease treatment medicine. The triterpene compound is any one or a mixture of two of maslinic acid and tormentic acid. The Parkinson's disease treatment medicine provided by the invention comprises a pharmaceutically acceptable auxiliary material as well as an effective dosage of any one or a mixture of two of the maslinic acid and the tormentic acid. The triterpene compounds, namely the maslinic acid and the tormentic acid, are capable of directly blocking mutual combination between the autophagy skeleton protein Beclin1 and the autophagy inhibiting factor Bcl-2, so that the triterpene compounds have the function of promoting autophagy in nerve cells, and have a nerve protection function on Parkinson's disease cells. Therefore, the maslinic acid and the tormentic acid can be directly adopted to prepare the Parkinson's disease treatment medicine, and the Parkinson's disease treatment medicine is endowed with good medicinal effect.
This trial is a randomised, double-blinded, placebo-controlled, polycentric study. The study consisted of a screening period (up to 2 weeks before randomization), a treatment period (24 weeks), and 4 follow-up visits (Weeks 0, 4, 12 and 24).

After a 2-week preparation period, 208 patients with SpA will be randomly and equally assigned to either experimental group consisting of BPG (injection form, 1.2 million units of intramuscular injection, once every two weeks) with ETN (injection form, 25mg of hypodermic injection, twice a week) or the control group consisting of placebos (injection form, once every two weeks) with ETN (injection form, 25mg of hypodermic injection, twice a week),with treatment lasting for 12 weeks. After 12 weeks of treatment, the label will be opened, and all patients will choose to use BPG combined with ETN maintenance therapy for another 12 weeks of treatment. Follow-up will be conducted at baseline, 4 weeks,12 weeks and 24 weeks after the end of treatment. The primary outcome is the response rate of ASAS20 in patients after 12 weeks of medication. The secondary outcomes are the severity of symptoms, disease activity, quality of life, and imaging progression scale scores of patients at each follow-up point. We will synchronize the recording of adverse events to compare the safety of the two treatment regimens
Sham Manip: Connective Tissue Massage (CTM) + Sham Spinal Manipulation (Sham SM) The intervention will be applied three times a week, starting from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. This will include treatment of the pelvic regions, specifically the sacral, lumbar, lower thoracic, and anterior pelvic areas. In addition to the CTM, sham spinal manipulation will be performed three times a week. This will involve the application of low-amplitude force bilaterally to all clinically relevant vertebral levels from T10 to L5 and to the sacroiliac joints, without producing any audible release. Treatment will be administered three times a week, with each session lasting 20 minutes. This regimen will continue for a duration of six weeks.
Alzheimer's disease (AD) is a degenerative illness accompanied by cognitive and memory loss. In addition to the widely accepted, convincing amyloid cascade hypothesis, the activation of glial cells and neuroinflammation, especially the microglia-mediated neuroinflammation, has an essential role in the development and progression of AD. Therefore, the anti-inflammatory treatment is becoming a promising therapeutic strategy. Aucubin (Au) is a natural product derived from many plants with anti-inflammatory and antioxidant activities. Up to now, no research has been conducted to investigate the anti-inflammatory effects of Au and its neuroprotective quality on AD and the potential molecular mechanisms of its medical roles. In our study, the results of network pharmacology revealed the potential therapeutic effect of Au on AD. The results of studies in vivo showed that Au improved the behaviors, counteracted cognitive and memory deficits, and ameliorated AD-like pathological features of the mouse brain, e.g., the deposition of Aβ plaques, neuronal damage, and inflammatory responses induced by glial cell overactivation, in APP/PS1 mice. The transcriptome sequencing further confirmed that the pathological symptoms of AD could be reversed by inhibiting the ERK/FOS axis to alleviate the inflammatory response. The in vitro experiments revealed that Au suppressed the BV2 cell activation, inhibited the phosphorylation of ERK1/2 and the expression of c-FOS, and reduced the LPS-induced inflammatory mediator production by BV2 cells and primary astrocytes. Our study suggested that Au exerted its neuroprotective effects by inhibiting the inflammatory responses, which could be a promising treatment of AD.
A patch structure 10 for transdermal therapy comprises a layer of sheet material 11 carrying copper particles 12 on or embedded in an adhesive pad 13 of foam or an elastomeric material. This may be in a ring formation about a zinc coated rare earth magnet 14. Alternatively there may be copper and zinc particles. Sheet material 11 carries a further layer 15 of adhesive for application to the skin. In use, very small electromagnetic impulses are generated which are particularly useful in the treatment of skeletal or muscular pain. The particulate material may also be a different metal, ceramic, gelatinous, soluble plastic, natural sponge or cellulose or any combination thereof. The particles may be spherical, cylindrical, hollow, solid or porous and may carry an active ingredient for therapy.
The present invention relates to Chinese medicine (Gutongning). The present invention comprises psoralea fruit, eucommia barks, radix cyathulae, peach kernel, angelica, spatholobus stems, hemlock parsley, phrymatolin, asarum herb, notoginseng, corydalis tuber, myrrh and curare. The ingredients are manufactured into various traditional Chinese medicine preparations through process steps such as cleaning, baking, pulverizing, leaching, concentrating, mixing, baking, fine crushing, secondary fine crushing, sieving, mixing, etc. The present invention has preeminent causal treatment effect on orthopedic diseases such as hyperosteogeny, etc. The present invention has no side effect, and can be used for both oral administration and external application. The present invention has the advantages of simultaneous internal and external treatment, major direction of causal treatment, dual effect of manifestation treatment and causal treatment, rapid medical effect taking, short course of treatment, outstanding curative effect, stable curative effect, simple production method and easy batch commercial process.
The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance Analysis (DSER), a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre- and post-treatment samples from a patient with BRCA2-deficient metastatic prostate cancer. FANCI and EYA4 were identified as candidate DNA repair-related targets for converting subclones from resistant to eradicable, and RNAi-mediated depletion of FANCI confirmed it as a potential target.  The EYA4 alteration was associated with adjacent L1 transposon insertion during cancer evolution upon treatment, raising questions surrounding the role of therapy in L1 activation. Both carboplatin and enzalutamide turned on L1 transposon machinery in LNCaP and VCaP but not in PC-3 and 22Rv1 prostate cancer cell lines. L1 activation in LNCaP and VCaP was inhibited by the antiretroviral drug azidothymidine. L1 activation was also detected post-castration in LuCaP 77 and LuCaP 105 xenograft models and post-chemotherapy in previously published time-series transcriptomic data from SCC25 head and neck cancer cells. In conclusion DSER provides an informative intermediate step toward effective precision cancer medicine and should be tested in future studies, especially those including dramatic but temporary metastatic tumor regression. L1 transposon activation may be a modifiable source of cancer genomic heterogeneity, suggesting the potential of leveraging newly discovered triggers and blockers of L1 activity to overcome therapy resistance.
In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of Fluticasone Propionate Cream was approximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively.

Two clinical studies compared once- to twice-daily administration of Fluticasone Propionate Cream for the treatment of moderate to severe eczema. The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1. In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years.

Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study. Fluticasone Propionate Cream was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%). The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) showed little change. In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were <18 µg/dL, indicating adrenal suppression. Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis. Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky erythema, resolving within 1 month after cessation of Fluticasone Propionate Cream; and telangiectasia, resolving within 3 months after stopping Fluticasone Propionate Cream.

The following local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria. Also, there are reports of the development of pustular psoriasis from chronic plaque psoriasis following reduction or discontinuation of potent topical corticosteroid products.
Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume "fettuccine" pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product.
The invention relates to the technical field of biomedicine, and particularly discloses an active peptide, an active peptide composition and application thereof. The amino acid sequence of the active peptide is shown as SEQ ID No.1 or SEQ ID No. 2. The active peptide composition comprises active peptides shown as SEQ ID No.1 and SEQ ID No. 2. The active peptide or the active peptide composition has the function of regulating facial flora; especially has effects of inhibiting proliferation of Staphylococcus epidermidis and Propionibacterium acnes, and promoting proliferation of Lactobacillus and Bacillus bifidus.
The spleen is an important mediator of both adaptive and innate immunity. As such, attempts to modulate the immune response provided by the spleen may be conducive to improved outcomes for numerous diseases throughout the body. Here, biomimicry is used to rationally design nanomaterials capable of splenic retention and immunomodulation for the treatment of disease in a distant organ, the postinfarct heart. Engineered senescent erythrocyte-derived nanotheranostic (eSENTs) are generated, demonstrating significant uptake by the immune cells of the spleen including T and B cells, as well as monocytes and macrophages. When loaded with suberoylanilide hydroxamic acid (SAHA), the nanoagents exhibit a potent therapeutic effect, reducing infarct size by 14% at 72 h postmyocardial infarction when given as a single intravenous dose 2 h after injury. These results are supportive of the hypothesis that RBC-derived biomimicry may provide new approaches for the targeted modulation of the pathological processes involved in myocardial infarction, thus further experiments to decisively confirm the mechanisms of action are currently underway. This novel concept may have far-reaching applicability for the treatment of a number of both acute and chronic conditions where the immune responses are either stimulated or suppressed by the splenic (auto)immune milieu.
GENTAK® Gentamicin sulfate is a water soluble antibiotic of the aminoglycoside group. 

Gentamicin sulfate ophthalmic ointment is a sterile ointment for ophthalmic use. Each gram contains gentamicin sulfate equivalent to 3 mg gentamicin in a base of white petrolatum and mineral oil, with methylparaben and propylparaben as preservatives. 

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1 C2, and C1A. All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows: